PostDoc in the Wherry Lab @ UPenn.
UPenn
Joined September 2009
- Tweets129
- Following284
- Followers240
- Likes366
Pinned Tweet
extremely excited to share our new story on the impact of JAK inhibition on responses to immune checkpoint blockade in lung cancer patients! 🧬🧑🔬 thread on our main findings 🧵 1/n
science.org/doi/10.1126/scie…
Divij retweeted
Very excited to get this new work by Shin Ngiow up on #bioRxiv. We may be blocking PD-1 too long causing detrimental effects on Tpex cells. A drug holiday approach may be beneficial. Also some cool new Tpex biology here. #immunopharmacology biorxiv.org/content/10.64898…
Divij retweeted
Excited to share my graduate work from the @EJohnWherry lab on the molecular mechanisms locking in the differentiation fate of exhausted CD8 T cells (Tex), published earlier this month in @SciImmuno. Main findings below!
science.org/doi/10.1126/scii…
Divij retweeted
What gets erased when you integrate single cell data, and can you recover it? Finally, we know what happens and how to recover the lost signals. So excited to share CellANOVA, published online today in NBT! go.nature.com/4hZnzW5
Recovery of biological signals lost in single-cell batch integration with CellANOVA go.nature.com/4hZnzW5
Divij retweeted
We are currently looking for a motivated Research Specialist to join the Apostolidis Lab! If you're passionate about understanding autoimmunity, doing cutting-edge science, and helping us build a collaborative and inclusive environment, we'd love to hear from you! Apply now 👇:
wd1.myworkdaysite.com/en-US/…
Divij retweeted
🚀Very excited to announce that the Apostolidis Lab will open up its doors on July 1st @PennMedicine! We will be focusing our efforts on understanding fundamental drivers of autoimmunity using unique human cohorts and mechanistic mouse models. #Autoimmunity #Rheumatology #OpenForScience
Divij retweeted
New research from @PennMedicine in @ScienceMagazine, led by PICI Investigators, shows promising results for advanced #NSCLC treatment in a Ph 2 trial: science.org/doi/10.1126/scie… (1/4)
Divij retweeted
Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w @EJohnWherry @divijmathew Caitlin Foley @MMarmarelis @Jbauml et al! 1/13
Divij retweeted
In two separate Science studies, researchers report that combining JAK inhibitors with checkpoint inhibitor immunotherapy enhances cancer patient response.
Learn more ⬇️
📄: scim.ag/7p1
📄: scim.ag/7p2
#SciencePerspective: scim.ag/7p0
9/n This study is a testament to the team science done at @PennMedicine with the translational work done in the amazing labs of @andyjminn @EJohnWherry
and the clinical effort led by @MMarmarelis @CoreyLangerMD @Jbauml
10/10 Big thanks to @facts___matter @MaxKlapholz
@NancyZh60672287 @Darwin_ye1 and all the coauthors instrumental in this effort, to the families and patients who participated in our study,and the support provided by @parkerici @UPenn_I3H @PennCancer @themarkfdn
Divij retweeted
and also excited today to see @divijmathew paper from the lab online now in @ScienceMagazine , a mammoth effort exploring how JAK inhibition modulates checkpoint immunotherapy responses! congratulations Divij!!! science.org/doi/10.1126/scie…
Divij retweeted
Scenes from @sitcancer Annual Conference in San Diego.
Excellent science, and thrilled to chair the Oral Abstract Session.
@PennCancer’s very own @divijmathew from @EJohnWherry lab presenting elegant science on FLT3 in NSCLC!
@AlGarfall @RobertFerrisMD @diwakardavar
Missed a pic w/ @PatelOncology @EladSharonMD – at San Diego, CA
